CTOs on the Move

Ceribell

www.ceribell.com

 
Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ceribell.com
  • 360 North Pastoria Avenue
    Sunnyvale, CA USA 94085
  • Phone: 800.436.0826

Executives

Name Title Contact Details
Therese Charles
Vice President Information Security & IT Profile

Funding

Ceribell raised $35M on 09/25/2018
Ceribell raised $20M on 05/01/2020
Ceribell raised $53M on 04/29/2021

Similar Companies

Ikaria

Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Hatec Inc

Hatec Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CM-Tec Inc

CM-Tec Inc is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rakuten Medical

Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company`s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has 6 locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland.

Viracta

Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.